Trial Profile
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms POP
- Sponsors Biogen
- 10 Feb 2022 Status changed from active, no longer recruiting to completed.
- 21 Apr 2020 Planned End Date changed from 24 Jan 2022 to 20 Jan 2022.
- 21 Apr 2020 Planned primary completion date changed from 24 Jan 2022 to 20 Jan 2022.